NEW YORK (GenomeWeb News) – Sequenom said this week that the California Technology Assessment Forum has completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's MaterniT21 Plus laboratory-developed test. According to the firm, CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high-risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.